Physician profile
John Thomas Dolehide
NPI 1811949712
$3,715.02
in general payments reported to CMS, 2019-2025
13 companies · $33.67 in 2025
The $33.67 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,503 · 2020: $335 · 2021: $582 · 2022: $494 · 2023: $539 · 2024: $228 · 2025: $33.67.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $801.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $800.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neotract INC. | $1,434.30 | 2019-2020 | |
| Teleflex LLC | $708.32 | 2021-2024 | Urolift |
| Boston Scientific Corporation | $398.73 | 2019-2023 | |
| Astellas Pharma US INC | $353.62 | 2019-2023 | Myrbetriq |
| Medtronic, INC. | $348.56 | 2022-2023 | Interstim |
| Abbvie INC. | $181.09 | 2023-2024 | Botox |
| Medtronic USA, INC. | $75.17 | 2020 | |
| Axonics, INC. | $70.15 | 2023 | Axonics, Bulkamid |
| Tolmar Pharmaceuticals, INC. | $67.97 | 2021-2022 | |
| 180 Medical, INC. | $24.15 | 2024 | Gentlecath Glide |
| Convatec INC. | $19.29 | 2024 | |
| Pfizer INC. | $17.18 | 2025 | |
| Coloplast Corp | $16.49 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Dolehide listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.